ATXI Stock Posts

ATXI Avenue Therapeutics6.29-2.18-25.7%

Premarket:2.50-3.79 (-60.3%)

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

Globe NewswireThu, 6-Oct 11:00 PM

ATXI Avenue Therapeutics14.50+2.99+26.0%

Premarket:12.41-2.09 (-14.4%)

Surge Battery Metals ($NILIF) in Focus as the U.S. Passes Inflation Reduction Act Placing a Big Bet on Battery Metals

AB Digital, Inc.Tue, 4-Oct 5:05 AM

ATXI Avenue Therapeutics10.08+2.83+39.0%

Premarket:9.40-0.68 (-6.8%)

Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Globe NewswireMon, 3-Oct 8:00 AM

ATXI Avenue Therapeutics4.21-0.15-3.4%

Premarket:2.17-2.04 (-48.5%)

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Globe NewswireMon, 14-Jun 7:00 AM

ATXI Avenue Therapeutics11.04+0.46+4.4%

Premarket:5.00-6.04 (-54.7%)

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Globe NewswireMon, 12-Oct 6:30 AM

ATXI Avenue Therapeutics Inc.4.16-0.03-0.7%

Premarket:5.44+1.28 (+30.8%)

InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

Globe NewswireTue, 13-Nov 6:30 AM